Thursday, September 4, 2025, Houston, Texas, 6:42 PM – 7:42 PM Central Time (7:42 PM – 8:42 PM Eastern Time)
Consensus or Controversy? Clinical Investigators Provide Perspectives on the Current and Future Care of Patients with Relapsed/Refractory Multiple Myeloma
Part 1 of a 2-Part CME/MOC-, NCPD- and ACPE-Accredited Satellite Symposium Series During the Society of Hematologic Oncology 2025 Annual Meeting
Event Details
Thursday, September 4, 2025
6:42 PM – 7:42 PM Central Time
Educational Dinner Meeting
Location
George R Brown Convention Center
1001 Avenida de las Americas
Houston, Texas
Phone: (713) 853-8000
Meeting Room
Level 3 in Grand Ballroom C (Theater Room 2)
Meletios-Athanasios (Thanos) C Dimopoulos, MD
Professor and Chairman
Plasma Cell Dyscrasias Unit
Section of Hematology and Medical Oncology
Department of Clinical Therapeutics
School of Medicine
National and Kapodistrian University of Athens
Alexandra Hospital
Athens, Greece
Hans Lee, MD
Director, Multiple Myeloma Research
Sarah Cannon Research Institute
Nashville, Tennessee
Noopur Raje, MD
Director, Center for Multiple Myeloma
Rita Kelley Chair in Oncology
Massachusetts General Hospital Cancer Center
Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Joseph Mikhael, MD, MEd
Professor, Clinical Genomics and Therapeutics
Translational Genomics Research Institute (TGen)
City of Hope Cancer Center
Chief Medical Officer
International Myeloma Foundation
Phoenix, Arizona
This activity is supported by educational grants from Bristol Myers Squibb, GSK, and Regeneron Pharmaceuticals Inc.
Agenda
Thursday, September 4, 2025
6:42 PM – 7:42 PM Central Time
Educational Dinner Meeting
Registration will be 15 minutes prior to the start of the meeting for onsite attendees.
Module 1: Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory (R/R) Multiple Myeloma (MM)
- Research documenting the effectiveness of idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel) for patients with heavily pretreated MM
- Published data from the Phase III KarMMa-3 and CARTITUDE-4 trials of ide-cel and cilta-cel, respectively, in earlier lines of treatment; recently presented overall survival (OS) findings from CARTITUDE-4
- Recent FDA approvals of ide-cel and cilta-cel in earlier settings; identification of appropriate candidates for CAR T-cell therapy and optimal sequencing with regard to other evidence-based approaches
- Spectrum, incidence and severity of acute and long-term toxicities with B-cell maturation antigen (BCMA)-directed CAR T-cell therapy in patients with MM; appropriate monitoring and management algorithms
- Early data with the GPRC5D-targeted CAR T-cell therapy arlocabtagene autoleucel for R/R MM; FDA RMAT (regenerative medicine advanced therapy) designation and ongoing evaluation in the Phase II QUINTESSENTIAL and Phase III QUINTESSENTIAL-2 studies
- Preliminary data and ongoing clinical research with other novel CAR T-cell platforms for R/R MM
Module 2: Integrating Bispecific Antibodies into the Management of R/R MM
- Similarities and differences in the cellular targets and mechanisms of action of the various approved and investigational bispecific antibodies for MM
- Available efficacy and safety findings leading to the FDA approvals of teclistamab and elranatamab for R/R MM; optimal incorporation into management algorithms
- Published findings with investigational anti-BCMA bispecific antibodies, such as linvoseltamab, for heavily pretreated MM; future clinical role
- Efficacy and safety data supporting the FDA approval of talquetamab for heavily pretreated MM; optimal sequencing and selection of candidates to receive this agent
- Spectrum, incidence and severity of cytokine release syndrome, neurotoxicity/immune effector cell-associated neurotoxicity syndrome and other toxicities with BCMA- and non-BCMA-targeted bispecific antibodies; optimal mitigation and management strategies
- Rationale for, early data with and ongoing studies of bispecific antibodies in combination with other bispecific antibody platforms or standard systemic therapies for MM
Module 3: Potential Role of Antibody-Drug Conjugates and Cereblon E3 Ligase Modulators (CELMoDs) in Therapy for MM
- Mechanism of action and structural components of belantamab mafodotin
- Key efficacy and safety data from the Phase III DREAMM-7 and DREAMM-8 trials evaluating belantamab mafodotin in combination with bortezomib/dexamethasone and pomalidomide/dexamethasone, respectively, for patients who have received 1 or more prior lines of therapy; recently presented OS findings from DREAMM-7
- Ongoing FDA review and potential role of belantamab mafodotin-based combination strategies in the management of R/R MM
- Incidence, severity, mitigation and management of belantamab mafodotin-related adverse events, including ocular toxicities
- Mechanism of action of CELMoDs; similarities and differences among iberdomide, mezigdomide and standard immunomodulatory drugs
- Available data documenting the efficacy and safety of iberdomide and mezigdomide as monotherapy and combined with other systemic therapies for patients with R/R MM
- Ongoing Phase III studies, such as EXCALIBER-RRMM, SUCCESSOR-1 and SUCCESSOR-2, attempting to define the role of CELMoDs in the care of patients with R/R MM
CE Information
Target Audience
This activity has been designed to meet the educational needs of hematologists, hematology-oncology fellows, medical oncologists, pharmacists, nurse practitioners, clinical nurse specialists and other healthcare professionals involved in the treatment of multiple myeloma.
Learning Objectives
Upon completion of this activity, participants should be able to
- Consider published research findings and other clinical factors in the best-practice sequencing of established and novel agents and regimens in the care of patients with relapsed/refractory (R/R) multiple myeloma (MM).
- Evaluate published research findings to identify patients with R/R MM for whom treatment with chimeric antigen receptor T-cell therapy directed at B-cell maturation antigen (BCMA) should be considered or recommended.
- Assess available research data with BCMA- and non-BCMA-directed bispecific antibodies for MM in order to appropriately integrate these agents into clinical algorithms.
- Recall recently presented clinical research establishing the definitive efficacy of BCMA-directed antibody-drug conjugate therapy for patients with R/R MM.
- Analyze the mechanism of action of, published efficacy and safety findings with and ongoing research evaluating cereblon E3 ligase modulators, and use this information to prepare for the potential clinical availability of these agents for patients with R/R MM.
- Implement a plan of care to recognize and manage class-effect and agent-specific toxicities associated with therapies commonly administered to patients with R/R MM.
CE Credit
CME/MOC, NCPD and ACPE credit information will be given to each participant as part of the meeting course materials.
Accreditation, Support and Credit Statements
In support of improving patient care, Medical Learning Institute Inc is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
Medical Learning Institute Inc (MLI) designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Participation information will be shared through the ACCME's Program and Activity Reporting System (PARS).
For Physicians requesting MOC credit, the post-test and evaluation are required in their entirety as well as your ABIM ID number, DOB (MM/DD), and a score of 70% or higher is needed to obtain MOC credit.
Please note, this program has been specifically designed for the following ABIM specialties: medical oncology and hematology.
Nursing Continuing Professional Development
Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour and 1.0 contact hour in the area of pharmacology.
Continuing Pharmacy Education
Medical Learning Institute Inc designates this knowledge-based continuing education activity for 1.0 contact hour (0.1 CEU) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA0007322-0000-25-031-L01-P
For Pharmacists, MLI will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, view your participation record at the NABP website: https://nabp.pharmacy/
Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
This activity will be submitted to the ONCC for ILNA verification.
Commercial Support Statement
This CE activity is supported through educational grants from Bristol Myers Squibb, GSK, and Regeneron Pharmaceuticals Inc.
Disclosure and Conflict of Interest Policy
Medical Learning Institute Inc and Research To Practice are committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education. To that end, MLI requires faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to MLI policy. Faculty disclosures will be provided to learners prior to the start of the CE activity.
Planning Committee and Content/Peer Reviewers — The planners and content/peer reviewers from Medical Learning Institute Inc, the accredited provider, and Research To Practice, our educational partner, do not have any relevant financial relationship(s) to disclose with ineligible companies.
Disclosure of Unlabeled Use
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
This symposium is planned and provided by Medical Learning Institute Inc and Research To Practice. This accredited CME/MOC, NCPD and ACPE activity is an independent satellite symposium in conjunction with the Society of Hematologic Oncology 2025 Annual Meeting and is supported by Bristol Myers Squibb, GSK, and Regeneron Pharmaceuticals Inc.
FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
Prof Dimopoulos — Advisory Committees, Consulting Agreements and Speakers Bureaus: Amgen Inc, AstraZeneca Pharmaceuticals LP, BeOne, Bristol Myers Squibb, GSK, Janssen Biotech Inc, Menarini Group, Regeneron Pharmaceuticals Inc, Sanofi, Swixx Biopharma SA, Takeda Pharmaceutical Company Limited. Dr Lee — Consulting Agreements: Alexion Pharmaceuticals, Bristol Myers Squibb, GSK, Janssen Biotech Inc, Menarini Group, Pfizer Inc, Regeneron Pharmaceuticals Inc, Sanofi, Takeda Pharmaceuticals USA Inc; Contracted Research: Alexion Pharmaceuticals. Amgen Inc,Bristol Myers Squibb, GSK, Janssen Biotech Inc, Regeneron Pharmaceuticals Inc, Takeda Pharmaceuticals USA Inc; Data and Safety Monitoring Boards/Committees: Allogene Therapeutics, Takeda Pharmaceuticals USA Inc. Dr Raje — Advisory Committees: Advisor to AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Genentech, a member of the Roche Group, GSK, Johnson & Johnson, Pfizer Inc, Sanofi.
MODERATOR — Dr Mikhael — Consulting Agreements: Bristol Myers Squibb, Janssen Biotech Inc, Menarini Group, Sanofi.
Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
Location
George R Brown Convention Center
1001 Avenida de las Americas
Houston, TX 77010
Main Phone: (713) 853-8000
Meeting Room
Level 3 in Grand Ballroom C (Theater Room 2)
Directions
The George R Brown Convention Center is the main venue for the SOHO 2025 Annual Meeting.
Registration
There is no registration fee for this event. For the in-person symposium in Houston, preregistration is required as seating is limited.
NOTICE:
In order to attend in person, you must also be registered to attend the SOHO 2025 Annual Meeting. Registration for this event is independent of registration for the 2025 SOHO Annual Meeting.
I am a practicing physician, fellow, nurse or other healthcare provider involved in the treatment of cancer.
IN-PERSON Registrationfor clinicians »
Please note, a limited number of seats are available to other/industry professionals on a first come, first served basis.
IN-PERSON Registrationfor nonclinicians »
Please note, we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions.
REGISTRATION FOR WEBCAST »Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.
Research To Practice fully complies with the legal requirements of the ADA. If you require any physical, dietary or other accommodations, please call us at (800) 233-6153 before the event.
If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153.